• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Fayers, P M
    Rustin, G
    Wood, R
    Nelstrop, A
    Leonard, R C F
    Wilkinson, Peter M
    Cruickshank, D
    McAllister, E J
    Redman, C W E
    Parker, D
    Scott, I V
    Slevin, M L
    Roulston, J E
    Show allShow less
    Affiliation
    MRC Cancer Trials Office, Cambridge CB2 2BB, Dept. of Medical Oncology, Charing Cross Hospital, London W6 8RF, Dept. of Oncology, Western General Hospital, Edinburgh EH4 2XU, Dept. of Oncology, Christie Hospital, Manchester M20 9BX, Dept. Obstet. & Gynaecol, Aberdeen Maternity Hospital, Aberdeen AB9 2ZA, Dept. of Biochemistry and Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, Dept. Obstetrics and Gynaecol, North Staffordshire Royal Infirmary, Stoke-on-Trent ST4 7LN, Clinical Oncology Unit, Bradford Royal Infirmary, Bradford BD9 6RJ, Dept. Obstetrics and Gynaecology, Derby City Hospital, Derby DE3 3NE, Dept. of Oncology, Homerton Hospital, London E9 6SR, Department of Clinical Biochemistry, Royal Infirmary, Edinburgh EH3 9YW, UK.
    Issue Date
    1993-09
    
    Metadata
    Show full item record
    Abstract
    A number of studies have suggested that serum CA 125 levels may be an important prognostic factor for survival of patients with ovarian carcinoma. We investigated, in a large group of patients from 11 UK centers, which combination of CA 125 measurements provided the best prognostic index, and whether the predictive power could be improved by the addition of other factors. Analysis of the data from 248 patients showed that the absolute value of the third CA 125 sample was the single most important factor for predicting progression at 12 months, with the addition of residual bulk only slightly improving the predictive power. Seventy-four patients had CA 125> 70, and of these 57% were correctly predicted to progress or die within 12 months, but 43% remained alive and progression free. The best predictor for progression produced a false positive rate of 19%. We therefore conclude that prognostic information based upon CA 125 measurements up to the start of the third course of initial chemotherapy is not accurate enough to be used to manage individual patients.
    Citation
    The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. 1993, 3 (5):285-292 Int. J. Gynecol. Cancer
    Journal
    International Journal of Gynecological Cancer
    URI
    http://hdl.handle.net/10541/99795
    DOI
    10.1046/j.1525-1438.1993.03050285.x
    PubMed ID
    11578359
    Type
    Article
    Language
    null
    ISSN
    1525-1438
    ae974a485f413a2113503eed53cd6c53
    10.1046/j.1525-1438.1993.03050285.x
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    • Authors: Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani AR
    • Issue date: 2004 Apr
    • Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    • Authors: Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R
    • Issue date: 2022 Sep 26
    • Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
    • Authors: Menon U, Gentry-Maharaj A, Burnell M, Ryan A, Kalsi JK, Singh N, Dawnay A, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Parmar M, Jacobs IJ, UKCTOCS team
    • Issue date: 2025 May
    • Prognostic value of CA 125 in advanced ovarian cancer.
    • Authors: Mogensen O
    • Issue date: 1992 Mar
    • Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
    • Authors: AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY
    • Issue date: 2024 Feb
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.